Erasca, Inc. (ERAS) Q3 2025 10-Q Quarterly Report
Erasca, Inc. (ERAS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 12, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Erasca, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • No new or changed risk factors reported versus 2024 10-K
- • Clinical trial delays and regulatory approvals remain key operational risks impacting near-term milestones
- • Dependence on a concentrated cash position, with liquidity sufficient through mid-2026 under current projections
- • Intellectual property litigation risk ongoing, with no new material developments this quarter
- • Competitive pressures from larger oncology firms persist, challenging clinical and commercial progress
Erasca, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$31M
▲ +1.9% YoY▲ +9.6% QoQ
ROE
-8.8%
Total Assets
$420M
EPS (Diluted)
$-0.11
▼ -57.1% YoY▲ +8.3% QoQ
Operating Cash Flow
-$22M
▲ +3.4% YoY▼ -5.5% QoQ
Source: XBRL data from Erasca, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Erasca, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.